Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

IntroductionHepatocellular carcinoma (HCC) patients at advanced stages receive immunotherapy or treatment with tyrosine kinase inhibitors (TKIs) such as Sorafenib (Sora) or Lenvatinib in frontline as well as Regorafenib (Rego) or Cabozantinib in second-line. A major hindrance of TKI therapies is the...

Full description

Bibliographic Details
Main Authors: Kristina Breitenecker, Viola Hedrich, Franziska Pupp, Doris Chen, Eva Řezníčková, Gregor Ortmayr, Heidemarie Huber, Gerhard Weber, Lorenz Balcar, Matthias Pinter, Wolfgang Mikulits
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
GAS6
Axl
tyrosine kinase inhibitors
Regorafenib
ErbB
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1238883/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1238883/full

Similar Items